Background. Our objective in this study was to demonstrate the safety and efficacy of iclaprim compared with vancomycin for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSIs).
Patients
The study randomized 598 patients who fulfilled criteria for the ITT population from 30 study sites in 6 countries. The ITT population, the prespecified efficacy population for FDA, included all randomized patients. The safety population was defined as all randomized patients who received at least 1 dose of study medication. Male and female patients aged ≥18 years with suspected or confirmed ABSSSI due to gram-positive pathogens were eligible for study participation. Key inclusion and exclusion criteria are listed in Table 1 .
Definitions
ABSSSI was defined as a bacterial infection of the skin with a lesion size ≥75 cm 2 . ABSSSIs were stratified as major cutaneous abscess, cellulitis/erysipelas, and/or wound infections (caused by external trauma [eg, needle sticks or insect bites]) and had the following characteristics: the presence of purulent or seropurulent drainage before or after surgical intervention of a wound or at least 3 of the following signs and symptoms: discharge, erythema (extending at least 2 cm beyond a wound edge in 1 direction), swelling and/or induration, heat and/or localized warmth, and/or pain and/or tenderness to palpation.
Early clinical response (ECR) was defined as a ≥20% reduction in lesion size compared with baseline. Early time point (ETP) was defined as 48-72 hours after the first infusion of study drug. End of treatment (EOT) was defined as the day the infusion of study drug was complete.
Clinical cure at the TOC visit was evaluated using 2 prespecified definitions. First, clinical cure at the TOC visit was defined as complete resolution of all signs and symptoms of ABSSSI such that no further antibiotic treatment or surgical procedure was needed at the TOC visit. This definition of clinical cure is used for pivotal phase 3 studies of ABSSSI and cSSSI. Second, clinical cure at TOC was also evaluated as a ≥90% reduction in lesion size compared with that at baseline, no increase in lesion size since ETP, and no requirement for additional antibiotics (except aztreonam or metronidazole for polymicrobial infections) or unplanned significant surgical procedures after ETP. This definition of clinical cure was intended to allow for an objective measure (ie, 90% reduction in lesion size) similar to the ECR (ie, 20% reduction in lesion size).
Assessments
Patients were evaluated at a baseline assessment, then evaluated daily through the ETP conducted at 48-72 hours after the first infusion of study drug and then every 48-72 hours through the EOT. Treatment duration was 5-14 days based on investigator assessment. Patients were then evaluated at the TOC assessment conducted 7-14 days post-EOT, followed by a late follow-up phone call conducted 28-32 days after the first dose ( Figure 1 ).
Safety was assessed using Common Terminology Criteria for reported treatment emergent adverse events (TEAEs), serious adverse events (SAEs), hematology, clinical chemistry, liver function tests, coagulation, urinalysis, vital signs, physical examinations, and electrocardiograms (ECGs).
Before randomization, adequate clinical specimens were obtained from patients at baseline, EOT, and TOC for microbiologic evaluation. The local microbiology laboratory evaluated the specimens, and isolates were subcultured and sent to a central microbiology laboratory for confirmation of pathogen 
Primary Endpoint and Secondary Analyses
The primary endpoint of the study was to compare the ECR (defined as a ≥20% reduction in lesion size at the ETP compared with baseline) at ETP (48-72 hours after the start of administration of the study drug) in the ITT population treated with iclaprim or vancomycin among patients with ABSSSI suspected or confirmed to be due to gram-positive pathogens. The secondary analyses of the study were clinical cure rate at TOC (7-14 days after the last dose of study drug compared with that at baseline) and safety and tolerability of iclaprim compared with vancomycin.
Study Treatments
Iclaprim was administered at 80 mg (no hepatic impairment or Child-Pugh A) or 40 mg IV every 12 hours (Child-Pugh B). Child-Pugh C patients were excluded from this study. The fixed dose was chosen based on a pharmacokinetic and pharmacodynamic analysis of 470 plasma samples obtained from efficacy and safety evaluations in previous phase 3 clinical studies [12] . Vancomycin was administered at 15 mg/kg IV and adjusted according to a nomogram with dosing every 12 hours (creatinine clearance [CrCl] ≥50), every 24 hours (CrCl ≥35-49), every 48 hours (CrCl ≥25-34), or according to daily vancomycin trough levels (CrCl <25). Trough levels were drawn at dose 5 for patients with normal renal function. An unblinded pharmacist prepared infusions for patients who were assigned to the vancomycin arm, notably keeping the same infusion volume as used for iclaprim. For each patient, the unblinded pharmacist used the CrCl or vancomycin trough levels (to which the investigator was blinded) to adjust the vancomycin dosage to maintain a trough of 10-15 mg/L for patients with an organism with an MIC ≤1 mg/L or 15-20 mg/L for those with an MIC >1 mg/L. Both iclaprim and vancomycin were infused over 120 minutes in 500 mL normal saline. Normal saline placebo infusions were used to maintain the blind where vancomycin was dosed at an interval greater than every 12 hours. The protocol permitted concomitant antibiotic treatment with aztreonam or metronidazole for patients in whom gram staining of culturable material or cultures indicated gram-negative and anaerobic bacteria, respectively. Systemic antibiotics (other than aztreonam and metronidazole) or topical antibiotics at the site of the ABSSSI under investigation were prohibited.
Duration of Treatment
Patients received their first dose of randomly allocated study medication within 24 hours after randomization. Study medications were administered for at least 5 days, with continuation of treatment up to 14 days at the investigator's discretion based on the assessment of resolution of signs and symptoms of the ABSSSI. This duration of treatment was in accordance with the Infectious Disease Society of America (IDSA) guidelines [13] .
Statistical Methods
A total of 600 patients (approximately 300 per treatment group) randomized (1:1) were targeted for this study. Using Farrington and Manning's method for noninferiority testing with a 1-sided alpha of 0.025 and assuming a 75% ECR rate in each group and a 10% noninferiority bound delta, a sample size of 295 ITT patients per treatment group was required for 80% power. In the statistical analyses, we evaluated the efficacy and safety of iclaprim compared with vancomycin. Statistical tests were 2-sided and at the level of significance alpha = 0.05. The noninferiority assessment was made with a 1-sided test at a significance level of 0.025. Confidence intervals (CIs) were calculated at a 95% confidence level. Continuous data were summarized by treatment group using the number of patients in the analysis population (N), mean, standard deviation, median, and range, and categorical data were summarized by treatment group using N and percentage. Demographics and baseline characteristics were summarized using descriptive statistics. The primary efficacy analysis was performed in the ITT population. Secondary analyses were performed in the ITT-predefined populations that included those that had diabetes and mild, moderate, and severe renal impairment. By-patient and by-pathogen bacteriological outcomes at EOT and TOC were presented as frequency distributions of outcomes by treatment group for patients with a confirmed gram-positive pathogen at baseline. The incidence of TEAEs was summarized at the overall patient level, Medical Dictionary for Regulatory Activities version 18.1 system organ class level, and preferred term level. Separate tabulations were provided by severity and relationship to study medication and for SAEs. Laboratory data, vital signs, and ECGs were evaluated by presentation of summary statistics of raw data and changes from baseline. Figure 2 shows the disposition of patients. The baseline and demographic characteristics of patients treated with either iclaprim or vancomycin were comparable (Tables 2 and 3 ). The baseline mean (standard deviation) lesion sizes of iclaprim and vancomycin were 333 cm 2 (317.1) and 337 cm 2 (317.5), respectively. Treatment groups were similar for baseline ABSSSI categories, laboratory parameters, vital signs, physical examinations, X-rays, and ECG evaluations. In addition, no notable differences among treatment groups with respect to prior medications and treatments or study drug compliance were observed. Both the iclaprim and vancomycin treatment groups had the same median number of treatment days at 7 days (range, 5-14 days).
RESULTS

Demographics
Efficacy Results
Primary Endpoint
In the ITT population, an ECR was reported at ETP for 80.9% (241/298) of patients in the iclaprim group and for 81.0% (243/300) of patients in the vancomycin group (% difference, −0.13; 95% CI, −6.42, 6.17; Table 3 ).
Secondary Analyses
In the ITT population, the clinical cure rates at EOT were 92.3% Figure 2 . Disposition of patients. Two patients were randomized in error by a site because the patients reported they were unable or unwilling to adhere to study-designated procedures and restrictions. No baseline screening or study drug were administered to these 2 patients.
were methicillin resistant ( Table 2 ). The MIC 50 /MIC 90 values for iclaprim and vancomycin for S. aureus isolates were 0.12/0.5 μg/ mL and 1/1 μg/mL, respectively.
Safety Results
Study drug-related TEAEs, treatment emergent SAEs, and deaths among patients in the iclaprim and vancomycin treatment groups are shown in Table 5 . The TEAEs that led to discontinuation were 2.7% in patients in the iclaprim group and 4.4% in patients in the vancomycin group. Compared to patients in the vancomycin group, there was an increased incidence of headache (10.2% and 2.4%), nausea (9.9% and 5.7%), secondary ABSSSI (6.8% and 3.3%), and fatigue (6.1% and 3.0%) in patients in the iclaprim group. There were no study drug-related TEAEs related to nephrotoxicity reported for iclaprim compared to 3 TEAEs (1.0%; acute kidney injury) for vancomycin. The creatinine change from baseline to TOC was 2.9 and 7.2 µmol/L in patients in the iclaprim group compared to the vancomycin group. There were no significant differences between treatment groups in mean values or mean changes in other routine serum laboratory parameters, urinalysis results, vital signs, or physical examinations during treatment or at EOT, TOC, and follow-up between treatment groups. Fifteen (5.5%) patients in the iclaprim group and 10 (3.8%) patients in the vancomycin group had increases in alanine aminotransferase or aspartate aminotransferase values to >3 times upper limit of normal (ULN) during treatment.These increases resolved to baseline values upon discontinuation of the drugs in all patients. No patient had bilirubin increases >2 times ULN. No patients met Hy's law criteria in this study.
One (0.4%) patient in the iclaprim group and 0 patients in the vancomycin group had corrected QT interval by Fredericia (QTcF) intervals >500 milliseconds (ie, 527 milliseconds) or increased by >60 milliseconds compared with baseline. For the 1 patient with a corrected QT (QTc) prolongation, an AE was not reported and resolved to baseline values upon discontinuation of the drug.
DISCUSSION
This phase 3 study clinical trial met its primary endpoint, demonstrating that iclaprim is noninferior to vancomycin in the treatment of ABSSSI caused by gram-positive organisms with respect to ECR at the ETP of 48-72 hours after the first teria: fulfilled the published definition for systemic inflammatory response syndrome by having 2 or more of the following findings: body temperature >38°C or <36°C, heart rate >90 bpm, respiration rate >20 breaths/minute, and white blood cell count >12 000/mm 3 or <4000/mm 3 or >10% bands; evaluated as having severe tenderness or severe erythema at the infection site; and/or positive blood cultures at baseline. dose of study drug. No notable differences in the incidence of TEAEs between the treatment groups were observed. The iclaprim dosage used in this study was fixed (ie, 80 mg) over a 120-minute infusion, rather than the weight-based dosing of 0.8 mg/kg used in previous studies. The weight-based dosing resulted in 1 phase 3 study of cSSSI within and 1 outside the noninferiority margin of >10%. As a result, iclaprim was not approved by the FDA for the indication of cSSSI. Data that support the fixed dose were based on modeling of population pharmacokinetics and pharmacodynamics from 470 patients who received a weight-based 0.8-mg/kg dose of iclaprim in previous phase 3 cSSSI studies [14] . A population pharmacokinetic analysis of the data from the 470 patients demonstrated no relationship between the clearance of iclaprim and body weight, suggesting that a fixed rather than weight-based dose should be used. The estimates of the individual patient pharmacokinetic parameters were used to simulate the plasma iclaprim concentration-time profiles for each patient and from those profiles, the corresponding values for C max/ss , area under the curve (AUC)(0-24) ss , AUC/MIC, and time > MIC. In these analyses, the MIC value used was based on the MIC 90 of S. aureus of 0.12 mg/mL, which was identified in worldwide surveillance studies [8] . Various fixed-dose regimens were examined with respect to maximizing AUC/MIC and time > MIC while minimizing the probability of a steady-state C max (C max/ss ) ≥800 ng/mL. This fixed dose was projected to result in a 30% increase in AUC/ MIC and time > MIC, parameters associated with efficacy in animal infection models, while allowing for an approximately The order of the TEAE by system organ class was listed in the order of most frequent (top) to least frequent (bottom) for iclaprim.
Abbreviations: QTc, corrected QT; SAE, severe adverse event; TEAE, treatment emergent adverse events. *Investigator reported. 10% decrease in C max , a parameter associated with QTc prolongation in phase 1 studies compared with the weight-based dose of iclaprim [15] . The IDSA guidelines for the management of adults with ABSSSI include use of vancomycin, linezolid, or daptomycin, which are all generic, against susceptible MRSA, for the empiric treatment of suspected ABSSSI in patients with risk factors for MRSA [13] . Safety issues or resistance to vancomycin, linezolid, and daptomycin are reported among patients treated for MRSA infections [12, [16] [17] [18] [19] [20] . The results of this study suggest that iclaprim may be a useful treatment option for ABSSSI due to gram-positive pathogens, especially since it has an appropriate spectrum of activity, is effective, is not nephrotoxic, and does not require therapeutic drug monitoring nor renal dosing adjustments.
There are limitations to this phase 3 study. First, 70% (419 out 598) of participants in this study were from the United States, 28% (170 of 598) from Europe, and 1.5% (9 of 298) from Latin America. No countries from Asia-Pacific were included in this study. Second, it is often challenging to collect appropriate microbiological samples in cellulitis, and only 8.3% (50 of 598) of cultures or ASO titers were positive for beta-hemolytic streptococci. Despite attempts to enrich for Streptococci pyogenes by leading-edge punch biopsies and serological tests, the percentage of patients with an infection documented to be due to these bacteria was low. Third, data on vancomycin trough concentrations were not collected at the central laboratory. Vancomycin dosing based on vancomycin trough concentrations at the local laboratories was not available. However, based on the vancomycin nomogram, more than 95% of patients had the correct dosing interval for this antibiotic. Fourth, there was an imbalance in the number of patients lost to follow-up between the iclaprim (5.7%; N = 17) and vancomycin (2.0%; N = 6) treatment groups. Among the patients lost to follow-up, 94% (16 of 17) in the iclaprim and 100% (6 of 6) in the vancomycin groups were intravenous drug users of heroin or amphetamine. As indicated in a prespecified statistical analyses plan, all patients lost to follow-up were considered noncures. Fifth, an underpowered modified clinical cure analysis defined by a ≥90% reduction in lesion size compared with baseline, no increase in lesion size since ETP, and no requirement for additional antibiotics at TOC was used. This secondary analysis used an arbitrary reduction (≥90%) in lesion size compared with baseline at TOC. Post-inflammatory changes (eg, erythema, swelling, and/or induration) may linger for weeks despite resolution of the infection and explain why a lower, modified clinical cure was observed at TOC. Sixth, more than 50% of ABSSSI randomized were wound infections. For both wound infections and abscesses, surgical therapy is vital to treatment.
In conclusion, in this phase 3 study, iclaprim was noninferior to vancomycin with respect to the ECR at an ETP in the treatment of ABSSSI caused or suspected by gram-positive organisms. These results suggest iclaprim may serve as an alternative option for treatment of ABSSSI caused by gram-positive pathogens, including drug-resistant bacteria.
